Drugs Containing Excipient (Inactive Ingredient) PEG-8

« Back to Dashboard

Branded drugs containing PEG-8 excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	PREMARIN	estrogens, conjugated	50090-0167	PEG-8
Bausch Health US LLC	KLARON	sulfacetamide sodium	0187-5198	PEG-8 LAURATE
Cosette Pharmaceuticals Inc	ACEPHEN	acetaminophen	0713-0118	PEG-8 STEARATE
Rising Pharma Holdings Inc	SULFAMYLON	mafenide acetate	16571-723	PEG-8 STEARATE

Generic drugs containing PEG-8 excipient

Company	Ingredient	NDC	Excipient
A-S Medication Solutions	estrogens, conjugated	50090-0167	PEG-8
A-S Medication Solutions	metronidazole	50090-0201	PEG-8
A-S Medication Solutions	cefuroxime axetil	50090-0782	PEG-8
A-S Medication Solutions	valacyclovir hydrochloride	50090-1173	PEG-8

PEG-8 Pharmaceutical Excipient Market Dynamics, Supply Chain, Regulation, and Financial Outlook

Last updated: October 4, 2026

PEG-8 is a low-molecular-weight polyethylene glycol used primarily as a solvent, humectant, plasticizer, vehicle, and formulation aid. The pharmaceutical market is fragmented, and manufacturers do not generally report PEG-8 revenue as a standalone category. The most reliable commercial indicators are demand for pharmaceutical-grade polyethylene glycol, especially PEG 300 and PEG 400, along with broader growth in oral liquids, topical products, soft capsules, and parenteral formulations.

PEG-8 has limited standalone patent risk. Its core composition is long established, is not an FDA-listed drug substance, and does not have an Orange Book patent estate. Commercial value depends more on grade qualification, impurity control, supply continuity, and customer-specific regulatory files than on exclusivity.

What is PEG-8 and how is it used in pharmaceuticals?

PEG-8 is a polyethylene glycol with an average ethoxylation level of approximately eight ethylene oxide units. Commercial nomenclature is not fully standardized across pharmaceutical, cosmetic, and chemical markets.

Attribute	PEG-8 profile
Chemical family	Polyethylene glycol
Common chemical name	Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-hydroxy-
CAS number commonly associated with PEG	25322-68-3
Approximate molecular-weight range	Usually associated with low-molecular-weight PEG grades
Pharmaceutical analogues	Macrogol 300, macrogol 400, PEG 300, PEG 400
Primary functions	Solvent, vehicle, humectant, plasticizer, wetting aid
Dosage forms	Oral liquids, softgels, tablets, creams, ointments, gels, ophthalmic and veterinary products
Drug status	Excipient, not an active pharmaceutical ingredient
Orange Book status	No standalone listing
Biosimilar relevance	None

PEG nomenclature creates a material commercial issue. “PEG-8” can refer to a low-molecular-weight polyethylene glycol in one product specification, while “PEG-8 caprylic/capric glycerides” refers to a different nonionic surfactant used in lipid-based formulations. Those materials should not be treated as interchangeable.

The pharmaceutical-grade market typically buys to compendial or customer specifications rather than to the cosmetic INCI name. USP-NF and Ph. Eur. monographs identify polyethylene glycol grades by molecular-weight and quality characteristics rather than by a universal “PEG-8” designation.[1,2]

What pharmaceutical functions does PEG-8 perform?

PEG-8 and closely related low-molecular-weight PEG grades are used where water miscibility, low volatility, and chemical compatibility are required.

Solvent and vehicle

PEG 300 and PEG 400 dissolve or solubilize selected active ingredients and excipients in oral, topical, and liquid formulations. They can reduce reliance on ethanol or propylene glycol, although the choice depends on toxicity, taste, viscosity, route of administration, and drug compatibility.

Humectant and moisture-control agent

PEG retains water and can improve product feel and stability. In topical products, it modifies spreadability and reduces drying. In solid dosage forms, it can affect moisture migration and tablet mechanical properties.

Plasticizer

Low-molecular-weight PEGs plasticize polymers such as cellulose derivatives and selected film-forming systems. They can change flexibility, tensile properties, tack, and drug-release behavior.

Softgel and capsule processing

PEG-based vehicles are used in some softgel and liquid-fill systems. Compatibility with gelatin, shell composition, active ingredient, and capsule-processing conditions must be established through product-specific qualification.

Permeation and release modification

PEG can alter wetting, diffusion, and polymer hydration. Its effect on release is formulation dependent. A PEG-containing formulation is not automatically a controlled-release formulation.

How large is the PEG-8 pharmaceutical excipient market?

No major public company or regulatory agency reports global revenue for PEG-8 as a discrete pharmaceutical excipient. Market estimates that combine PEG, polyethylene glycol, PEG derivatives, surfactants, and cosmetic ingredients cannot be used as direct PEG-8 pharmaceutical revenue.

The addressable market is best analyzed through four layers:

Market layer	Commercial relevance to PEG-8
Pharmaceutical-grade PEG 300/400	Core market proxy
All pharmaceutical polyethylene glycols	Broader volume and pricing proxy
Cosmetic and personal-care PEG-8	Separate, usually larger nomenclature pool
PEG derivatives and PEGylation reagents	Different products and economics

Pharmaceutical demand is linked to generic and specialty-drug manufacturing, topical and oral-liquid development, softgel production, and excipient replacement programs. PEG demand also benefits from growth in contract development and manufacturing, because CDMOs purchase qualified excipients for multiple customer programs.

The financial trajectory is therefore a volume-and-mix story rather than a patent-driven product cycle. Low-molecular-weight PEG is generally a mature, scale-manufactured chemical. Price performance depends on ethylene oxide costs, energy, plant utilization, freight, packaging, regional capacity, and quality documentation.

What is driving PEG-8 demand?

Growth in oral liquids and topical products

PEG 300 and PEG 400 remain useful in formulations that require a water-miscible organic vehicle. Demand rises with products that cannot achieve adequate solubility or stability in water alone.

Drug solubility challenges

Poor aqueous solubility remains a major formulation constraint. PEG is one of several solvent and cosolvent options used to address it. Competitive materials include propylene glycol, glycerin, ethanol, polysorbates, poloxamers, medium-chain triglycerides, and specialized lipid excipients.

Outsourcing to CDMOs

CDMOs often maintain approved supplier lists for excipients. Once a PEG grade is qualified in a commercial formulation, substitution can require comparability work, stability data, and regulatory assessment. This creates customer retention even when the underlying material is not patent protected.

Demand for high-purity and low-impurity grades

Pharmaceutical customers increasingly differentiate between industrial PEG and grades with documented control of aldehydes, peroxides, ethylene oxide-related impurities, 1,4-dioxane, heavy metals, microbial quality, and elemental impurities. High-purity grades carry better margins than undifferentiated industrial material.

What factors could limit PEG-8 market growth?

PEG-8 faces substitution risk from other solubilizers and excipients. Formulators may select propylene glycol, glycerol, ethanol, poloxamers, polysorbates, hydroxypropyl beta-cyclodextrin, lipid vehicles, or newer enabling excipients based on route and toxicity requirements.

The main technical constraints are:

• Potential irritation in sensitive topical or mucosal applications.
• Taste and gastrointestinal tolerability in oral liquids.
• Oxidative degradation and peroxide formation in some storage conditions.
• Compatibility concerns with active ingredients, polymers, capsule shells, and packaging.
• Patient or regulatory scrutiny of residual ethylene oxide and related impurities.
• Supply-chain dependence on ethylene oxide and downstream ethoxylation capacity.

PEGs can also be unsuitable for certain parenteral applications where impurity controls, oxidation stability, or route-specific toxicology requirements are stringent.

Who supplies pharmaceutical-grade PEG-8 and related PEG grades?

The competitive field includes large chemical producers and specialty excipient suppliers. The relevant product may be sold as PEG 300, PEG 400, macrogol 300, macrogol 400, or a proprietary pharmaceutical-grade PEG rather than as “PEG-8.”

Supplier or group	Relevant commercial positioning
BASF	Kollisolv PEG grades and pharmaceutical excipient portfolio
Dow	CARBOWAX SENTRY polyethylene glycol grades
Clariant	Pharmaceutical and personal-care excipient materials
Croda	Super Refined and specialty pharmaceutical excipients
NOF Corporation	Pharmaceutical-grade PEG and PEG derivatives
India-based manufacturers	Cost-competitive PEG and macrogol supply, subject to qualification
Chinese manufacturers	Broad PEG capacity, with qualification and documentation varying by supplier

Supplier competition is determined by compendial compliance, regulatory support, batch consistency, manufacturing-site history, technical service, and geographic redundancy. Price alone is rarely decisive for a registered drug product.

What is the FDA regulatory status of PEG-8?

PEG-8 is regulated as an excipient when used in a drug product. The FDA does not approve PEG-8 as an independent therapeutic product. FDA review occurs through the finished dosage form, where the applicant must establish the excipient’s identity, quality, safety, concentration, route, and function.

The FDA Inactive Ingredient Database provides precedent for inactive ingredients used in approved drug products, but the database does not replace product-specific review.[3] A listed PEG grade or related molecular-weight grade does not guarantee acceptance in every route, concentration, or dosage form.

Important regulatory controls include:

• USP-NF or Ph. Eur. compliance where applicable.
• Current Good Manufacturing Practice under 21 C.F.R. Parts 210 and 211.[4]
• Supplier qualification and change control.
• Residual-solvent and elemental-impurity assessment.
• Oxidation and peroxide monitoring where relevant.
• Container-closure compatibility.
• Stability data in the finished formulation.
• Documentation for animal-origin, allergen, GMO, and TSE/BSE status when required by the customer.

What patents protect PEG-8?

The basic PEG-8 composition is not protected by a commercially meaningful modern composition-of-matter patent estate. Polyethylene glycol chemistry has been publicly known and industrially practiced for decades.

IP category	PEG-8 risk assessment
Core composition patent	Low or effectively expired
Manufacturing process patent	Possible at specific sites or for specific process improvements
Purification patent	Possible, usually narrow
Formulation patent	Possible, owned by drug-product sponsors
Method-of-use patent	Possible for a finished medicine, not for PEG-8 itself
Supplier trade secret	Relevant to process control and impurity management
Trademark protection	Possible for product brands, not the molecule
Orange Book patent	None for PEG-8 as an excipient
Paragraph IV risk	Not applicable to the excipient itself

The main IP risk is indirect. A drug sponsor may patent a formulation containing PEG, a particular PEG concentration, a polymer combination, a release profile, or a therapeutic use. Those rights attach to the finished drug product, not to ordinary supply of PEG-8.

When does PEG-8 lose exclusivity?

PEG-8 does not have a drug-style exclusivity date. It is a mature excipient and has no FDA new-drug exclusivity period, pediatric exclusivity, orphan-drug exclusivity, or standalone Orange Book protection.

A PEG-containing medicine can have exclusivity or patent protection based on its active ingredient, formulation, dosage form, or method of use. That protection does not prevent other manufacturers from selling PEG-8 for unrelated products.

Are there Paragraph IV challenges involving PEG-8?

No conventional Paragraph IV pathway applies to PEG-8 itself. Paragraph IV certifications challenge patents listed in the FDA Orange Book for an approved drug application. An excipient is not independently approved through an abbreviated new drug application and is not normally the subject of a Paragraph IV filing.[5]

A generic applicant could challenge a PEG-containing drug product if the reference product has listed formulation or method-of-use patents. The challenge would concern the drug application, not the lawful manufacture or sale of PEG-8.

What manufacturing and supply-chain barriers affect PEG-8?

PEG is produced through ethoxylation chemistry involving ethylene oxide. The principal barriers are operational and quality based:

1. Safe handling of ethylene oxide and associated process hazards.
2. Access to reliable ethylene oxide and ethylene feedstocks.
3. Reactor capacity and production scale.
4. Control of molecular-weight distribution.
5. Removal or control of residual reactants and byproducts.
6. Validated cleaning, packaging, and traceability systems.
7. Multi-region inventory and transport capability.
8. Regulatory support for site changes and raw-material changes.

Pharmaceutical customers often require audits, quality agreements, certificates of analysis, change notifications, and inspection history. A supplier interruption can therefore create a longer qualification problem than the physical replacement of the material would suggest.

How strong is the commercial moat around PEG-8?

The molecule has a weak legal moat but a moderate qualification moat.

Moat type	Strength	Explanation
Patent protection	Low	Core composition is mature
Regulatory exclusivity	None	No standalone FDA exclusivity
Manufacturing know-how	Moderate	Impurity and consistency control matter
Customer switching costs	Moderate	Reformulation and stability work can be required
Scale economics	Moderate to high	Large producers benefit from capacity and procurement
Brand differentiation	Moderate	Pharmaceutical-grade documentation supports retention
Geographic defensibility	Variable	Regional supply and redundancy affect pricing

This structure supports stable, recurring demand but limits the possibility of monopoly pricing. Margins are strongest for validated, high-purity grades and weakest for industrial or lightly specified material.

What financial trajectory should investors expect?

PEG-8 should be modeled as a mature specialty-chemical excipient rather than as a high-growth pharmaceutical asset.

Base case

Volume growth tracks pharmaceutical manufacturing and formulation demand. Pricing remains exposed to feedstock and logistics cycles. Revenue growth is likely to be modest unless a supplier gains share through a shortage, new geographic capacity, or a proprietary high-purity grade.

Upside case

The strongest upside would come from:

• A supply disruption affecting qualified competitors.
• Growth in liquid and lipid-based drug delivery.
• Expanded use in specialty formulations.
• Premium demand for low-peroxide or highly purified grades.
• Increased CDMO production and dual-sourcing programs.

Downside case

Pressure could arise from:

• Substitution by propylene glycol, poloxamers, polysorbates, or lipid excipients.
• Excess ethoxylation capacity.
• Weak generic-drug volumes.
• Customer consolidation and purchasing pressure.
• Regulatory concerns involving impurities or route-specific tolerability.
• Qualification of lower-cost suppliers.

Public financial statements from diversified suppliers generally do not isolate PEG-8 or even pharmaceutical PEG revenue. Company-level analysis should therefore use segment sales, excipient portfolio disclosures, capacity announcements, and price trends rather than claim a standalone PEG-8 revenue figure.[6-9]

What litigation and licensing activity affects PEG-8?

There is no material standalone PEG-8 patent-litigation pattern comparable to litigation involving branded drugs. The relevant disputes are more likely to involve:

• Supplier nonconformance.
• Product liability.
• Contractual supply obligations.
• Trade secrets involving purification or process control.
• Drug-product formulation patents that include PEG.
• Regulatory responsibility for excipient changes.

Licensing is also generally indirect. Drug developers may license a formulation, delivery platform, or finished product that uses PEG, but PEG-8 itself is typically purchased under a supply agreement rather than licensed under a molecule-specific patent license.

Key Takeaways

• PEG-8 is a mature low-molecular-weight polyethylene glycol excipient with uses in solvents, vehicles, humectants, plasticizers, and liquid or topical formulations.
• The commercial name may refer to different materials, including PEG-8 caprylic/capric glycerides. Product identity must be established before market analysis.
• No reliable public standalone PEG-8 pharmaceutical revenue figure exists.
• The best market proxies are pharmaceutical-grade PEG 300 and PEG 400, macrogol demand, and broader excipient sales.
• PEG-8 has no meaningful standalone Orange Book, Paragraph IV, biosimilar, or FDA exclusivity exposure.
• Core composition patent risk is low. Manufacturing know-how, quality systems, and customer qualification create the main commercial barriers.
• Financial performance should be modeled around volume, purity premium, feedstock cost, capacity utilization, and supplier qualification rather than patent expiration.
• Supplier concentration and regulatory-grade documentation can support moderate pricing resilience, but substitution and commodity competition limit long-term margins.

FAQs

Is PEG-8 the same as PEG 400?

Not necessarily. PEG-8 is a nomenclature description based on ethoxylation level, while PEG 400 is a pharmaceutical grade defined by average molecular weight and compendial specifications. Commercial equivalence must be confirmed through supplier documentation.

Is PEG-8 safe for oral pharmaceutical use?

PEG excipients have established pharmaceutical use, but safety depends on molecular weight, dose, route, concentration, impurities, and the finished formulation. FDA acceptance is product specific.

Can PEG-8 be used in injectable drugs?

Potentially, but parenteral use requires route-specific justification, impurity controls, compatibility data, and finished-product review. Oral or topical precedent does not automatically support injectable use.

Does PEG-8 create a barrier to generic drug entry?

PEG-8 alone does not. A generic applicant may face formulation, bioequivalence, stability, or patent barriers associated with the finished drug product, but ordinary PEG-8 supply is not an exclusivity barrier.

Which PEG grade is most relevant for pharmaceutical procurement?

PEG 300 and PEG 400 are often the most commercially relevant low-molecular-weight grades for pharmaceutical formulations. The correct grade depends on molecular weight, viscosity, route, solubility, compendial status, and formulation performance.

References

1. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Polyethylene glycol. USP-NF. https://online.uspnf.com
2. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia: Macrogols. https://www.edqm.eu
3. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
4. Electronic Code of Federal Regulations. (2024). 21 C.F.R. Parts 210 and 211: Current good manufacturing practice for drugs. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C
5. U.S. Food and Drug Administration. (2024). ANDA submissions: Amendments and supplements for approved abbreviated applications. https://www.fda.gov/drugs
6. BASF SE. (2024). Pharma solutions: Kollisolv polyethylene glycol. https://pharma.basf.com
7. Dow Inc. (2024). CARBOWAX SENTRY polyethylene glycols. https://www.dow.com
8. Croda International Plc. (2024). Pharmaceutical excipients and super refined products. https://www.croda.com
9. Clariant AG. (2024). Healthcare and pharmaceutical excipients. https://www.clariant.com